A VISION TO BE THE BEST      

A- A A+

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Gregory M. Fox, M.D., F.A.C.S.

Dr. Fox CURRICULUM VITAE

NAME

  • Gregory M. Fox, M.D., F.A.C.S.

BIRTHDATE

  • July 22, 1961; Honolulu, Hawaii

WORK HISTORY

May 1, 1999 -PRESENT:

  • Retina Associates, P.A.
    Santa Fe Medical Building
    9301 W 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates. P.A.
    10100 N Ambassador Drive
    Suite 100
    Kansas City, MO 64153
  • Retina Associates, P.A.
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, P.A.
    3700 W 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, P.A.
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086
     

1998 – 2002:

  • Hunkeler Eye Center
    NovaMed Eye Surgery Center
    4321 Washington #6000
    Kansas City, Missouri

1997 – 1998:

  • Clinical Instructor, Active Staff
    Allegheny University Hospital – MCP
    Philadelphia, Pennsylvania
  • Active Staff
    St. Francis Hospital
    Wilmington, Delaware
  • Active Staff
    Medical Center of Delaware
    Wilmington, Delaware
  • Consulting Staff Physician
    St. Christopher’s Hospital
    Philadelphia, Pennsylvania

1994 – 1997:

  • Medical Officer
    Branch of Ophthalmic Devices
    Food and Drug Administration (FDA)
    Rockville, Maryland
  • Special Volunteer Staff
    Laboratory of Immunology Clinical Branch
    National Eye Institute
    Bethesda, Maryland

1993 – 1997:

  • Vitreoretinal Surgeon
    Department of Ophthalmology
    National Naval Medical Center
    Bethesda, Maryland
  • Assistant Professor of Surgery
    Uniformed Services University of Health Sciences
    Bethesda, Maryland

EDUCATION

Saguaro High School
Scottsdale, Arizona
1975-1979
University of Notre Dame
South Bend, Indiana
Degree – B.A.
1979-1983
University of Michigan
Medical School
Ann Arbor, Michigan
1983-1987
William Beaumont Hospital
Royal Oak, Michigan
Resident Transitional Intern
1987-1988
Bascom Palmer Eye Institute
Miami, Florida
Ophthalmology Resident
1988-1991
Bascom Palmer Eye Institute
Miami, Florida
Medical Retina Fellow
07/1991-12/1991
William Beaumont Hospital
Royal Oak, Michigan
Vitreo/Retinal Fellow
1992-1993

LICENSURE

  • Missouri State License
  • Kansas State License
  • Michigan State License
  • Pennsylvania State License
  • Delaware State License

BOARD CERTIFICATIONS

  • Diplomate, American Board of Ophthalmology (1992)
  • Diplomate, National Board of Medical Examiners (1988)

ORGANIZATIONS AND SOCIETIES

  • American Academy of Ophthalmology
  • American Uveitis Society
  • Umbo Society
  • Society of Military Ophthalmologists
  • Association for Research in Vision and Ophthalmology
  • Phi Beta Kappa
  • Executive Committee, Delaware Ophthalmologic Society
  • Medical Society of Delaware
  • Medical Advisory Committee, Blue Cross Blue Shield of Kansas City

CLINICAL RESEARCH

  • Alcon: C-04-59, Sub-Investigator, Interval Dose Evaluation of Anecortave Acetate for those with Neovascular AMD, 01/2005 – 02/2008.
  • Alcon: C-02-60, Sub-Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Sham for inhibition of CNV in Non-Exudative AMD, 01/2004-01/2009.
  • Alcon: C-01-99, Principle Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Visudyne for Subfoveal Exudative AMD.
  • Allergan: 206207-008, Sub-Investigator, Posurdex Retinal Vein Occlusion, 1/2005 – 02/2009.
  • Allergan: 206207-010, Sub-Investigator, Posurdex Diabetic Macular Edema, 3/2005 – present.
  • DRCR: Intravitreal Triamcinolone study B, Sub-Investigator, Focal laser treatment versus Intravitreal Injection Triamcinolone for treatment of Diabetic Macular Edema, 6/2005 – 10/2006.
  • Eli Lilly: Protein Kinase C ? Inhibitor – Principle investigator; Diabetic Retinopathy Study.
  • Eyetech: EOP1023, Sub-Investigator, Intravitreal injection of Pegaptanib Sodium administered every 6 weeks for Neovascular Age-Related Macular Degeneration, 09/2005 - 10/2008.
  • Eyetech: PRESERVE, Sub-Investigator, Intravitreal injection of Pegaptanib Sodium administered every 4 weeks vs. 6weeks for Diabetic Macular Edema, 09/2009 – present.
  • Eyetech: EOP1024, Sub-Investigator, Intravitreal injection of Pegaptanib Sodium administered every 6 weeks for NVAMD, DME, RVO to assess the effects on the corneal endothelium, 05/2010 - present.
  • Genaera: 301, Sub-Investigator, Squalamine Lactate IV infusion for treatment of Neovascular AMD, 9/2005 – 11/2006.
  • Genentech: FVF4165g, Principle Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion, 2/2008 –01/2010.
  • Genentech: FVF4166g, Principle Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 2/2008 –01/2010.
  • Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 08/2007 – present.
  • Genentech: FVF3426g, Principle Investigator, Open-Label Extension for subjects who completed a Genentech Sponsored Ranibizumab Study, 03/2009 - present
  • Genentech: FVF4295, Principle Investigator, Evaluation of Ranibizumab on ease of procedure and complications in PDR requiring vitrectomy, 09/2007 – present.
  • Genentech: FVF4579g, Principle Investigator, 0.5mg AND 2.0mg Ranibizumab administered monthly or PRN for Subfoveal Neovascular Age-Related Macular Degeneration, 06/2009 – present.
  • Inspire: Co-investigator; Intravitreal injection for rhegmatogenous retinal detachments.
  • Ista: VIT-02-08961X, Principle investigator; injections for severe vitreous hemorrhage.
  • Novartis: SMS995-804, Principle investigator; systemic injection to decrease the rate of progression to proliferative retinopathy in diabetics.
  • Ophthotech: OPH3000, Sub-Investigator, trial to establish the safety, tolerability, and pharmacokinetic profile of multiple Intravitreal injections of Volociximab as monotherapy or in combination with Lucentis for NVAMD, 10/2008 - 05/2010.
  • Ophthotech: OPH1001, Sub-Investigator, trial to establish the efficacy of Intravitreal Injections of E10030 given in combination with Lucentis for NVAMD, 04/2010 – present.
  • Prophylactic Treatment OF Age-Related Macular Degeneration study, Principle investigator; University of Pittsburgh Eye and Ear, sub-clinical diode laser treatment of non-exudative ARMD.
  • Pharmacia: 524-OPT-0065-002 SnET2 for Exudative ARMD. Principle investigator.
  • “Retinal Pigment Epithelial Transplantation to Complement Submacular Surgery.” Project in collaboration with the Center for Geriatric Research at Allegheny University.
  • “Assessing Patient Preferences for Visual acuity Loss.” Principal Investigator at the National Naval Medical Center for this collaborative project with NEI and Washington University.
  • “Prospective Evaluation of the Treatment of Fluid Overload in Patients with Diffuse Diabetic Macular Edema.” Co-investigator at the National Naval Medical Center.
  • “Treatment of Complex Retinal Detachments with Liquid Perfluorochemicals.” Co-investigator at the National Naval Medical Center.
  • “Treatment of Complex Retinal Detachments with Silicone Oil..” Co-investigator at the National Naval Medical Center

PUBLICATIONS:

  • Fox GM, Kuwabara TK, Wiggert B, Redmond TM, Hess HH, Chader GJ, Gery I. Autoimmune Uveoretinitis (EAU) Induced by IRBP and by S-Antigen. Clin Immunolol Immunopathol 1987; 43:256-264.
  • Fox GM, Redmond TM, Wiggert B, Kuwabara TK, Chader GJ, Gery I. Dissociation between Lymphocyte Activation for Proliferation and for the Capacity to Adoptively Transfer Uveoretinitis. J Immunol 1987; 138:3242-3246.
  • Gery I, Fox GM, Wiggert B, Redmond TM, Kuwabara TK, Vistica B, Chader GJ. EAU Induced by Interphotoreceptor Retinoid-binding Protein (IRBP: A New Experimental Entity. Modern Trends in Immunology and Immunopathology of the Eye. A Secchi and I Frigona Ed., Milan:Messon 1989; 60-63.
  • Gery I, Hirose S, McAllister C, Fox GM, Wiggert B, Redmond TM, Chader GJ, Kuwabara TK. Difference between the Inflammatory Reactions in the Retina and Pineal Glands in Rats with “EAU”. Trends in Immunology and Immunopathology of the Eye. A Secchi and I Frigona Ed., Milan:Messon 1989; 87-91.
  • Fox GM, Heilskov T, Smith JL. Cogan’s Syndrome and Seroreactivity to Lyme Borreliosis. J Clin Neuro-Ophthalmol 1990; 10:83-87.
  • Fox GM, Joondeph BC, Flynn HW, Pflugfelder SC, Roussel TJ. Delayed Onset Pseudophakic Endophthalmitis. Am J Ophthalmol 1991; 111:163-173.
  • Fox GM, Crouse CA, Chuang EL, et al. Detection of Herpes Virus DNA in Vitreous and Aqueous Specimens. Archives of Ophthalmol 1991; 109:266-271.
  • Lam BL, Sialowski RM, Fox GM, Glaser HS. Visual Loss in Pseudotumor Cerebri from Branch Retinal Artery Occlusion. Am J Ophthalmol 1991; 198:266-271.
  • Fox GM, Flynn HW Jr., Davis JL, Culbertson W. Causes of Reduced Vision in Long-term Follow-up after Surgery for Uveitic Cataract in Patients with Juvenile Rheumatoid Arthritis. Am J Ophthalmol 1992; 114(6):708-714.
  • Fox GM, Blumenkranz MS. Giant Retinal Pigment Epithelial Tears in Acute Retinal Necrosis. Am J Ophthalmol 1993; 116(3):302-306.
  • Fox GM, Blumenkranz MS, Iverson DA. A Better Way to Perform Diabetic Vitrectomy. Rev Ophthalmol 1995; 2:71-74.
  • Blumenkranz MS, Fox GM. Acute Retinal Necrosis, Retina-Vitreous-Macula, D Guyer Ed., WB Saunders 1999; Vol 1, 62:760-765.
  • Vision of the Missouri Optometric Association, “Clinical Trials in Diabetic Retinopathy”, April/May 2001.
  • Mazzuca DE, Shields CL, Sinha N, Bianciotto CG, Fox GM, Shields, JA, "Progressive Retinal Invasion and Vitreous Seeding From Optic Disc Melanocytoma", Clinical and Experimental Ophthalmology 2011.

PRESENTATIONS AND LECTURES (NATIONAL)

  • Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota FL, May 1986.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, FL, May 1990.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, poster presentation, Sarasota, FL, May 1991.
  • American Academy of Ophthalmology, Long-Acting Gas Intraocular Tamponade in Diabetic Vitrectomy, Dallas, TX, November 1992.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, poster presentation, Sarasota, FL, May 1993.
  • Cataract Surgery Course, Uniformed Services University; Dropped Nuclei., Bethesda, MD, March 1994.
  • Ocular Trauma Course, Uniformed Services University, Sympathetic Ophthalmia, Bethesda, MD, May 1994.
  • American Uveitis Society Meeting, Ocular Lymphoma Mimicking Chronic Postoperative Endophthalmitis, San Francisco, CA, October 1994.
  • Cataract Surgery Course, Uniformed Services University, Posterior Segment Complications of Cataract Surgery, Bethesda, MD, March 1995.
  • Panel Session, FDA, Status of Retinal Devices, Rockville, MD, May 1995.
  • Medical Officer Presentation of VitreonTM and PerfluoronTM, Panel Session, FDA, Rockville, MD, October 1995.
  • Tropical Medicine Course, Uniformed Services University, Ocular Infestations, Bethesda, MD, February 1996.
  • Resident Lecture Series, Temple University, Current Issues in Retinal Diseases, Philadelphia, PA, December 1997.
  • MOA annual convention – October 9, 2000, “Update on Treatment for ARMD”.
  • Optometric Society of Greater Kansas City – February 5, 2001, “Update on Treatment for Complications of Diabetic Retinopathy”.

PRESENTATIONS AND LECTURES (INTERNATIONAL)

  • Master of Science for Clinical Optometry Course, Retinal Diseases: A Primer, Berlin, Germany, February 1997.
  • Master of Science for Clinical Optometry, Ocular Pathology, Oslo, Norway, April 1998.

A Vision to be the Best

Retina Associates, PA

9301 W 74th St Ste 210
Shawnee Mission, KS 66204

 

Map of our location

Email Us

From (E-mail Address):
Hello, my name is I am interested in scheduling an appointment with your Retina Associates, P.A. and would like to receive information about
Please call me at at your earliest convenience. Thank You!